You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePregabalin
Accession NumberDB00230  (APRD01198)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational
Description

Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica. It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S. [Wikipedia]

Structure
Thumb
Synonyms
(S)-3-Isobutyl gaba
3-Isobutyl gaba
CI-1008
Lyrica
S-(+)-3-isobutylgaba
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Pregabalincapsule100 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Pregabalincapsule75 mgoralActavis Pharma Company2013-03-06Not applicableCanada
Act Pregabalincapsule50 mgoralActavis Pharma Company2013-03-06Not applicableCanada
Act Pregabalincapsule25 mgoralActavis Pharma Company2013-03-06Not applicableCanada
Act Pregabalincapsule300 mgoralActavis Pharma Company2013-03-06Not applicableCanada
Act Pregabalincapsule225 mgoralActavis Pharma Company2013-03-06Not applicableCanada
Act Pregabalincapsule200 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Pregabalincapsule150 mgoralActavis Pharma Company2013-03-06Not applicableCanada
Auro-pregabalincapsule150 mgoralAuro Pharma Inc2015-03-02Not applicableCanada
Auro-pregabalincapsule75 mgoralAuro Pharma Inc2015-03-02Not applicableCanada
Auro-pregabalincapsule300 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-pregabalincapsule50 mgoralAuro Pharma Inc2015-03-02Not applicableCanada
Auro-pregabalincapsule225 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-pregabalincapsule25 mgoralAuro Pharma Inc2015-03-02Not applicableCanada
Auro-pregabalincapsule200 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-pregabalincapsule100 mgoralAuro Pharma IncNot applicableNot applicableCanada
Dom-pregabalincapsule75 mgoralDominion Pharmacal2013-09-09Not applicableCanada
Dom-pregabalincapsule50 mgoralDominion Pharmacal2013-09-09Not applicableCanada
Dom-pregabalincapsule225 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-pregabalincapsule25 mgoralDominion Pharmacal2013-09-09Not applicableCanada
Dom-pregabalincapsule300 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-pregabalincapsule150 mgoralDominion Pharmacal2013-09-09Not applicableCanada
Gd-pregabalincapsule150 mgoralGenmed A Division Of Pfizer Canada Inc2013-02-152015-09-30Canada
Gd-pregabalincapsule75 mgoralGenmed A Division Of Pfizer Canada Inc2013-02-152015-09-30Canada
Gd-pregabalincapsule50 mgoralGenmed A Division Of Pfizer Canada Inc2013-02-152015-09-01Canada
Gd-pregabalincapsule25 mgoralGenmed A Division Of Pfizer Canada Inc2013-02-152015-09-01Canada
Gd-pregabalincapsule300 mgoralGenmed A Division Of Pfizer Canada Inc2013-02-152015-09-01Canada
Gd-pregabalincapsule225 mgoralGenmed A Division Of Pfizer Canada Inc2013-02-152015-09-30Canada
Ipg-pregabalincapsule50 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule25 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule300 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule225 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule200 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule150 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule100 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-pregabalincapsule75 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-pregabalincapsule300 mgoralJamp Pharma Corporation2015-09-28Not applicableCanada
Jamp-pregabalincapsule150 mgoralJamp Pharma Corporation2015-09-28Not applicableCanada
Jamp-pregabalincapsule75 mgoralJamp Pharma Corporation2015-09-28Not applicableCanada
Jamp-pregabalincapsule50 mgoralJamp Pharma Corporation2015-09-28Not applicableCanada
Jamp-pregabalincapsule25 mgoralJamp Pharma Corporation2015-09-28Not applicableCanada
Lyricacapsule25 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralDispensing Solutions, Inc.2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralH.J. Harkins Company, Inc.2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralA S Medication Solutions2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralLake Erie Medical & Surgical Supply, DBA Quality Care Products, LLC2011-11-08Not applicableUs
Lyricacapsule100 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-18Not applicableUs
Lyricacapsule100 mg/1oralPd Rx Pharmaceuticals, Inc.2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralA S Medication Solutions2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralPhysicians Total Care, Inc.2006-11-01Not applicableUs
Lyricacapsule150 mg/1oralDispensing Solutions, Inc.2004-12-30Not applicableUs
Lyricacapsule100 mgoralPfizer Canada IncNot applicableNot applicableCanada
Lyricacapsule50 mg/1oralH.J. Harkins Company, Inc.2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralU.S. Pharmaceuticals2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralPd Rx Pharmaceuticals, Inc.2004-12-30Not applicableUs
Lyricacapsule200 mgoralPfizer Canada IncNot applicableNot applicableCanada
Lyricacapsule300 mg/1oralRebel Distributors Corp2004-12-30Not applicableUs
Lyricasolution20 mg/mLoralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralH.J. Harkins Company, Inc.2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralA S Medication Solutions2004-12-30Not applicableUs
Lyricacapsule200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-27Not applicableUs
Lyricacapsule75 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule300 mg/1oralPd Rx Pharmaceuticals, Inc.2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralPhysicians Total Care, Inc.2005-12-20Not applicableUs
Lyricacapsule300 mg/1oralbryant ranch prepack2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralDIRECT RX2015-01-01Not applicableUs
Lyricacapsule200 mg/1oralRebel Distributors Corp2005-06-10Not applicableUs
Lyricacapsule225 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Lyricacapsule150 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-06Not applicableUs
Lyricacapsule50 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralPd Rx Pharmaceuticals, Inc.2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralPhysicians Total Care, Inc.2005-10-19Not applicableUs
Lyricacapsule200 mg/1oralbryant ranch prepack2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralDIRECT RX2014-01-01Not applicableUs
Lyricacapsule150 mg/1oralRebel Distributors Corp2005-06-10Not applicableUs
Lyricacapsule300 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule300 mgoralPfizer Canada Inc2005-07-18Not applicableCanada
Lyricacapsule75 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-10Not applicableUs
Lyricacapsule50 mg/1oralSTAT Rx USA LLC2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralCardinal Health2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule25 mg/1oralbryant ranch prepack2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralRebel Distributors Corp2005-06-10Not applicableUs
Lyricacapsule200 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule225 mgoralPfizer Canada Inc2009-11-18Not applicableCanada
Lyricacapsule200 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralCardinal Health2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralbryant ranch prepack2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Lyricacapsule75 mg/1oralRebel Distributors Corp2005-06-10Not applicableUs
Lyricacapsule150 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule150 mgoralPfizer Canada Inc2005-07-18Not applicableCanada
Lyricacapsule150 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule225 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralSTAT Rx USA LLC2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralRebel Distributors Corp2005-06-10Not applicableUs
Lyricacapsule100 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule75 mgoralPfizer Canada Inc2005-07-18Not applicableCanada
Lyricacapsule100 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule300 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule225 mg/1oralRebel Distributors Corp2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralCardinal Health2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule100 mg/1oralbryant ranch prepack2004-12-30Not applicableUs
Lyricacapsule200 mg/1oralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Lyricacapsule25 mg/1oralRebel Distributors Corp2005-06-10Not applicableUs
Lyricacapsule75 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule50 mgoralPfizer Canada Inc2005-07-18Not applicableCanada
Lyricacapsule25 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule200 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule300 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-13Not applicableUs
Lyricacapsule25 mg/1oralCardinal Health2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralbryant ranch prepack2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Lyricacapsule50 mg/1oralSTAT Rx USA LLC2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralParke Davis Div Of Pfizer Inc2004-12-30Not applicableUs
Lyricacapsule25 mgoralPfizer Canada Inc2005-07-18Not applicableCanada
Lyricacapsule300 mg/1oralUnit Dose Services2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralA S Medication Solutions Llc2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-30Not applicableUs
Lyricacapsule150 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-06Not applicableUs
Lyricacapsule150 mg/1oralA S Medication Solutions2004-12-30Not applicableUs
Lyricacapsule25 mg/1oralPhysicians Total Care, Inc.2006-08-29Not applicableUs
Lyricacapsule150 mg/1oralH.J. Harkins Company, Inc.2004-12-30Not applicableUs
Lyricacapsule75 mg/1oralU.S. Pharmaceuticals2004-12-30Not applicableUs
Lyricacapsule50 mg/1oralPd Rx Pharmaceuticals, Inc.2004-12-30Not applicableUs
Mar-pregabalincapsule25 mgoralMarcan Pharmaceuticals Inc2014-11-26Not applicableCanada
Mar-pregabalincapsule300 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pregabalincapsule225 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pregabalincapsule200 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pregabalincapsule150 mgoralMarcan Pharmaceuticals Inc2014-11-26Not applicableCanada
Mar-pregabalincapsule75 mgoralMarcan Pharmaceuticals Inc2014-11-26Not applicableCanada
Mar-pregabalincapsule100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pregabalincapsule50 mgoralMarcan Pharmaceuticals Inc2014-11-26Not applicableCanada
Mint-pregabalincapsule50 mgoralMint Pharmaceuticals Inc2014-06-12Not applicableCanada
Mint-pregabalincapsule75 mgoralMint Pharmaceuticals Inc2014-06-12Not applicableCanada
Mint-pregabalincapsule225 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pregabalincapsule300 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pregabalincapsule25 mgoralMint Pharmaceuticals Inc2014-06-12Not applicableCanada
Mint-pregabalincapsule200 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pregabalincapsule100 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pregabalincapsule150 mgoralMint Pharmaceuticals Inc2014-06-12Not applicableCanada
Myl-pregabalincapsule25 mgoralMylan Pharmaceuticals Ulc2013-07-24Not applicableCanada
Myl-pregabalincapsule50 mgoralMylan Pharmaceuticals Ulc2013-07-14Not applicableCanada
Myl-pregabalincapsule300 mgoralMylan Pharmaceuticals Ulc2013-07-24Not applicableCanada
Myl-pregabalincapsule150 mgoralMylan Pharmaceuticals Ulc2013-07-24Not applicableCanada
Myl-pregabalincapsule225 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Myl-pregabalincapsule75 mgoralMylan Pharmaceuticals Ulc2013-07-24Not applicableCanada
Mylan-pregabalincapsule300 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-pregabalincapsule150 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-pregabalincapsule75 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-pregabalincapsule50 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-pregabalincapsule225 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-pregabalincapsule25 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Pendo-pregabalincapsule150 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pendo-pregabalincapsule50 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-pregabalincapsule50 mgoralPharmascience Inc2013-02-14Not applicableCanada
PMS-pregabalincapsule25 mgoralPharmascience Inc2013-02-14Not applicableCanada
PMS-pregabalincapsule225 mgoralPharmascience Inc2013-02-19Not applicableCanada
PMS-pregabalincapsule300 mgoralPharmascience Inc2013-02-14Not applicableCanada
PMS-pregabalincapsule150 mgoralPharmascience Inc2013-02-14Not applicableCanada
PMS-pregabalincapsule75 mgoralPharmascience Inc2013-02-14Not applicableCanada
Pregabalincapsule50 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule25 mgoralPro Doc Limitee2013-02-15Not applicableCanada
Pregabalincapsule150 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pregabalincapsule225 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule225 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pregabalincapsule225 mgoralSanis Health IncNot applicableNot applicableCanada
Pregabalincapsule25 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule225 mgoralSivem Pharmaceuticals Ulc2013-03-27Not applicableCanada
Pregabalincapsule75 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pregabalincapsule200 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule300 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule300 mgoralSanis Health Inc2013-06-12Not applicableCanada
Pregabalincapsule300 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Pregabalincapsule300 mgoralSivem Pharmaceuticals Ulc2013-03-27Not applicableCanada
Pregabalincapsule50 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pregabalincapsule150 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule150 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Pregabalincapsule150 mgoralSivem Pharmaceuticals Ulc2013-03-27Not applicableCanada
Pregabalincapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Pregabalincapsule25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pregabalincapsule100 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule225 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule150 mgoralSanis Health Inc2013-06-12Not applicableCanada
Pregabalincapsule75 mgoralSivem Pharmaceuticals Ulc2013-03-27Not applicableCanada
Pregabalincapsule300 mgoralPro Doc Limitee2013-02-15Not applicableCanada
Pregabalincapsule75 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule200 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule75 mgoralSanis Health Inc2013-06-12Not applicableCanada
Pregabalincapsule75 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Pregabalincapsule50 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule150 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule50 mgoralSanis Health Inc2013-06-12Not applicableCanada
Pregabalincapsule50 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Pregabalincapsule50 mgoralSivem Pharmaceuticals Ulc2013-03-27Not applicableCanada
Pregabalincapsule150 mgoralPro Doc Limitee2013-02-15Not applicableCanada
Pregabalincapsule100 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule25 mgoralSanis Health Inc2013-06-12Not applicableCanada
Pregabalincapsule25 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Pregabalincapsule25 mgoralSivem Pharmaceuticals Ulc2013-03-27Not applicableCanada
Pregabalincapsule75 mgoralPro Doc Limitee2013-02-15Not applicableCanada
Pregabalincapsule25 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule75 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Pregabalincapsule50 mgoralPro Doc Limitee2013-02-15Not applicableCanada
Pregabalincapsule300 mgoralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Pregabalincapsule300 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pregabalin Capsulescapsule50 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule75 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule25 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule300 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule225 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule200 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule150 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin Capsulescapsule100 mgoralLUPIN LIMITEDNot applicableNot applicableCanada
Pregabalin-150capsule150 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Pregabalin-225capsule225 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Pregabalin-25capsule25 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Pregabalin-300capsule300 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Pregabalin-50capsule50 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Pregabalin-75capsule75 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Ran-pregabalincapsule300 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-02-15Not applicableCanada
Ran-pregabalincapsule225 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-02-15Not applicableCanada
Ran-pregabalincapsule150 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-02-15Not applicableCanada
Ran-pregabalincapsule75 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-02-15Not applicableCanada
Ran-pregabalincapsule50 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-02-15Not applicableCanada
Ran-pregabalincapsule25 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-02-15Not applicableCanada
Ratio-pregabalincapsule25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule225 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule200 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule100 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule300 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule150 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule75 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-pregabalincapsule50 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Riva-pregabalincapsule225 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pregabalincapsule300 mgoralLaboratoire Riva Inc2013-02-15Not applicableCanada
Riva-pregabalincapsule150 mgoralLaboratoire Riva Inc2013-02-15Not applicableCanada
Riva-pregabalincapsule75 mgoralLaboratoire Riva Inc2013-02-15Not applicableCanada
Riva-pregabalincapsule50 mgoralLaboratoire Riva Inc2013-02-15Not applicableCanada
Riva-pregabalincapsule25 mgoralLaboratoire Riva Inc2013-02-15Not applicableCanada
Sandoz Pregabalincapsule75 mgoralSandoz Canada Incorporated2013-02-15Not applicableCanada
Sandoz Pregabalincapsule50 mgoralSandoz Canada Incorporated2013-02-15Not applicableCanada
Sandoz Pregabalincapsule25 mgoralSandoz Canada Incorporated2013-02-15Not applicableCanada
Sandoz Pregabalincapsule300 mgoralSandoz Canada Incorporated2013-02-15Not applicableCanada
Sandoz Pregabalincapsule150 mgoralSandoz Canada Incorporated2013-02-15Not applicableCanada
Teva-pregabalincapsule225 mgoralTeva Canada Limited2013-02-15Not applicableCanada
Teva-pregabalincapsule300 mgoralTeva Canada Limited2013-02-15Not applicableCanada
Teva-pregabalincapsule150 mgoralTeva Canada Limited2013-02-15Not applicableCanada
Teva-pregabalincapsule75 mgoralTeva Canada Limited2013-02-15Not applicableCanada
Teva-pregabalincapsule50 mgoralTeva Canada Limited2013-02-15Not applicableCanada
Teva-pregabalincapsule200 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Teva-pregabalincapsule25 mgoralTeva Canada Limited2013-02-15Not applicableCanada
Teva-pregabalincapsule100 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule50 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule25 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule300 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule225 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule200 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule150 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule100 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pregabalincapsule75 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pregabalincapsule300 mgoralApotex Inc2013-04-22Not applicableCanada
Apo-pregabalincapsule225 mgoralApotex Inc2013-05-09Not applicableCanada
Apo-pregabalincapsule150 mgoralApotex Inc2013-04-22Not applicableCanada
Apo-pregabalincapsule75 mgoralApotex Inc2013-04-22Not applicableCanada
Apo-pregabalincapsule50 mgoralApotex Inc2013-06-06Not applicableCanada
Apo-pregabalincapsule25 mgoralApotex Inc2013-06-06Not applicableCanada
Pregabalincapsule150 mg/1oralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII55JG375S6M
CAS number148553-50-8
WeightAverage: 159.2261
Monoisotopic: 159.125928793
Chemical FormulaC8H17NO2
InChI KeyInChIKey=AYXYPKUFHZROOJ-ZETCQYMHSA-N
InChI
InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
IUPAC Name
(3S)-3-(aminomethyl)-5-methylhexanoic acid
SMILES
CC(C)C[[email protected]](CN)CC(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentGamma amino acids and derivatives
Alternative Parents
Substituents
  • Gamma amino acid or derivatives
  • Medium-chain fatty acid
  • Branched fatty acid
  • Amino fatty acid
  • Fatty acyl
  • Fatty acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationPregabalin is used for the management of neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, and postherpetic neuralgia. It is also used as adjunctive therapy for adult patients with partial onset seizures and management of fibromyalgia.
PharmacodynamicsPregabalin is a new anticonvulsant drug indicated as an add on therapy for partial onset seizures and for certain types of neuropathic pain. It was designed as a more potent successor to a related drug, gabapentin. Pregabalin binds to the alpha2-delta subunit of the voltage-gated calcium channel in the central nervous system. While pregabalin is a structural derivative of the inhibitory neurotransmitter gamma- aminobutyric acid (GABA), it does not bind directly to GABAA, GABAB, or benzodiazepine receptors, does not augment GABAA responses in cultured neurons, does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons prolonged application of pregabalin increases the density of GABA transporter protein and increases the rate of functional GABA transport. Pregabalin does not block sodium channels, is not active at opiate receptors, and does not alter cyclooxygenase enzyme activity. It is inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.
Mechanism of actionPregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in pregabalin's antinociceptive and antiseizure effects in animal models. In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function. Studies also suggest that the descending noradrenergic and serotonergic pathways originating from the brainstem may be involved with the mechanism of pregabalin. Interestingly, although pregabalin is a structural derivative of inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors. The sodium channels, opiate receptors, and cyclooxygenase enzymes are not involved with the mechanism of pregabalin. It is also inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.
Related Articles
AbsorptionPregabalin is well absorbed after oral administration. When an oral administration of pregabalin under fasting conditions is given, the pharmacokinetic parameters are as follows: Tmax = 1.5 hours; Oral bioavailability = >90% (independent of dose); Time to steady state = 24-48 hours. It is also a substrate for the L-type transport system.
Volume of distribution

Apparent volume of distribution, oral administration = 0.5 L/kg.
Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats.

Protein bindingPregabalin does not bind to plasma proteins.
Metabolism

Pregabalin undergoes negligible metabolism in humans.

Route of elimination90% of the dose was recovered in the urine as the parent compound. The N-methylated derivative of pregabalin, the major metabolite was found in the urine and accounted for 0.9% of the dose. Pregabalin (S-enantiomer) did not undergo racemization to the R-enantiomer.
Half life6.3 hours
Clearance

Renal clearance, healthy subjects = 67.0 – 80.9 mL/min. Because pregabalin is not bound to plasma protein, this rate suggests the involvement of renal tubular reabsorption.

ToxicityMost common adverse reactions (≥5% and twice placebo) are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9727
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6531
P-glycoprotein substrateNon-substrate0.683
P-glycoprotein inhibitor INon-inhibitor0.965
P-glycoprotein inhibitor IINon-inhibitor0.9424
Renal organic cation transporterNon-inhibitor0.9245
CYP450 2C9 substrateNon-substrate0.8758
CYP450 2D6 substrateNon-substrate0.7926
CYP450 3A4 substrateNon-substrate0.6914
CYP450 1A2 substrateNon-inhibitor0.9385
CYP450 2C9 inhibitorNon-inhibitor0.9425
CYP450 2D6 inhibitorNon-inhibitor0.9539
CYP450 2C19 inhibitorNon-inhibitor0.9629
CYP450 3A4 inhibitorNon-inhibitor0.9352
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9784
Ames testNon AMES toxic0.938
CarcinogenicityNon-carcinogens0.5678
BiodegradationReady biodegradable0.8201
Rat acute toxicity1.7046 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9868
hERG inhibition (predictor II)Non-inhibitor0.8909
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral150 mg
Capsuleoral150 mg/1
Capsuleoral200 mg
Capsuleoral200 mg/1
Capsuleoral225 mg/1
Capsuleoral225 mg
Capsuleoral25 mg/1
Capsuleoral25 mg
Capsuleoral300 mg
Capsuleoral300 mg/1
Capsuleoral50 mg
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Capsuleoral75 mg
Solutionoral20 mg/mL
Prices
Unit descriptionCostUnit
Lyrica 100 mg capsule2.88USD capsule
Lyrica 150 mg capsule2.88USD capsule
Lyrica 50 mg capsule2.88USD capsule
Lyrica 75 mg capsule2.88USD capsule
Lyrica 200 mg capsule2.75USD capsule
Lyrica 225 mg capsule2.75USD capsule
Lyrica 25 mg capsule2.75USD capsule
Lyrica 300 mg capsule2.75USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2297163 No2001-11-202018-08-18Canada
CA2327285 No2005-06-142019-05-10Canada
US5563175 No1993-10-082013-10-08Us
US6001876 No1998-12-302018-12-30Us
US6197819 No1998-12-302018-12-30Us
USRE41920 No1998-12-302018-12-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble FDA label
logP-1.35FDA label
pKa4.2 and 10.6 FDA label
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-1.4ALOGPS
logP-1.3ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)4.8ChemAxon
pKa (Strongest Basic)10.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity43.68 m3·mol-1ChemAxon
Polarizability18.08 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Mark Burk, “Asymmetric synthesis of pregabalin.” U.S. Patent US20030212290, issued November 13, 2003.

US20030212290
General References
  1. Authors unspecified: Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005 Jul 28;70(144):43633-5. [PubMed:16050051 ]
  2. Su TZ, Feng MR, Weber ML: Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15. Epub 2005 Mar 15. [PubMed:15769862 ]
  3. Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, Cui M, Hoffman D, Donevan S: Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011 Sep 30;667(1-3):80-90. doi: 10.1016/j.ejphar.2011.05.054. Epub 2011 Jun 1. [PubMed:21651903 ]
External Links
ATC CodesN03AX16
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (3.46 MB)
MSDSDownload (106 KB)
Interactions
Drug Interactions
Drug
AzelastinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pregabalin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pregabalin.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
BuprenorphinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pregabalin.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pregabalin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pregabalin.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pregabalin.
EthanolPregabalin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pregabalin.
HydrocodonePregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pregabalin.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pregabalin.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
MefloquineThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mefloquine.
MethotrimeprazinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MetyrosinePregabalin may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Pregabalin can be decreased when used in combination with Mianserin.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
MirtazapinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pregabalin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
OrlistatThe serum concentration of Pregabalin can be decreased when it is combined with Orlistat.
OrphenadrinePregabalin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydePregabalin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pregabalin.
PioglitazonePregabalin may increase the fluid retaining activities of Pioglitazone.
PramipexolePregabalin may increase the sedative activities of Pramipexole.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pregabalin.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pregabalin.
RopinirolePregabalin may increase the sedative activities of Ropinirole.
RosiglitazonePregabalin may increase the fluid retaining activities of Rosiglitazone.
RotigotinePregabalin may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pregabalin.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
SuvorexantPregabalin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
ThalidomidePregabalin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pregabalin.
TroglitazonePregabalin may increase the fluid retaining activities of Troglitazone.
ZolpidemPregabalin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol (may increase CNS effects).
  • When taken with food, Cmax decreases, while Tmax is prolonged. Despite these observations, the total absorption of pregabalin is not effected to a clinically relevant degree. Pregabalin can be taken with or without food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to...
Gene Name:
CACNA1A
Uniprot ID:
O00555
Molecular Weight:
282362.39 Da
References
  1. Gazulla J, Tintore M: The P/Q-type voltage-dependent calcium channel: a therapeutic target in spinocerebellar ataxia type 6. Acta Neurol Scand. 2007 May;115(5):356-63. [PubMed:17489948 ]
  2. Gazulla J, Tintore MA: The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses. 2007;68(1):131-6. Epub 2006 Aug 8. [PubMed:16899342 ]
  3. Jacquy J, Lossignol D, Sternon J: [Pregabalin (Lyrica) and neuropathic pain syndromes]. Rev Med Brux. 2006 Sep-Oct;27(5):445-50. [PubMed:17144644 ]
  4. Taylor CP, Angelotti T, Fauman E: Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007 Feb;73(2):137-50. Epub 2006 Nov 28. [PubMed:17126531 ]
  5. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D: Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17537-42. Epub 2006 Nov 6. [PubMed:17088553 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
Other
General Function:
Sodium:dicarboxylate symporter activity
Specific Function:
Transports L-glutamate, L- and D-aspartate and L-cystein (PubMed:21123949). Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium. Negatively regulated by ARL6IP5 (By similarity).
Gene Name:
SLC1A1
Uniprot ID:
P43005
Molecular Weight:
57099.835 Da
References
  1. Ryu JH, Lee PB, Kim JH, Do SH, Kim CS: Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anaesth. 2012 Aug;109(2):234-9. doi: 10.1093/bja/aes120. Epub 2012 Apr 16. [PubMed:22511482 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 29, 2016 02:11